Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027

Biogen leans on newly acquired Apellis' Empaveli and Syfovre to offset Leqembi's disappointing Alzheimer's sales ahead of Q2 earnings.

Raccontata daendpoints.news